Population Pharmacokinetics of Darbepoetin in Infants Following Single Intravenous and Subcutaneous Dosing.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Pharmacy and Science

• Publication date

  2017-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.xphs.2017.02.001PMID 28189627PMCID PMC6190690
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Stretchable self-tuning MRI receive coils based on liquid metal technology (LiquiTune)

  2021cited by this paper
• Population Pharmacokinetics of Darbepoetin Alfa in Conjunction with Hypothermia for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy

  2015cited by this paper
• Epidemiology of neonatal encephalopathy and hypoxic-ischaemic encephalopathy.

  2010cited by this paper
• NEUROPROTECTIVE EFFECT OF ERYTHROPOIETIN AND DARBEPOETIN ALFA AFTER EXPERIMENTAL INTRACEREBRAL HEMORRHAGE

  2009cited by this paper
• Population pharmacokinetics of darbepoetin alfa in healthy subjects.

  2007cited by this paper
• Intravenous administration of darbepoetin to NICU patients

  2006cited by this paper
• Single-Dose Darbepoetin Administration to Anemic Preterm Neonates

  2005cited by this paper
• Adverse Neurodevelopmental Outcomes Among Extremely Low Birth Weight Infants With a Normal Head Ultrasound: Prevalence and Antecedents

  2005cited by this paper
• Once-Monthly Administration of Darbepoetin Alfa for the Treatment of Patients with Chronic Heart Failure and Anemia: A Pharmacokinetic and Pharmacodynamic Investigation

  2005cited by this paper
• Diurnal variations of serum erythropoietin in trained and untrained subjects

  2004cited by this paper
• Passage of erythropoietic agents across the blood-brain barrier: a comparison of human and murine erythropoietin and the analog darbepoetin alfa.

  2004cited by this paper
• Treatment of Anemia with Aranesp® (Darbepoetin-alfa) Given Once Every Two Weeks in HIV Seropositive Patients.

  2004cited by this paper
• Optimizing the use of erythropoietic agents-- pharmacokinetic and pharmacodynamic considerations.

  2002cited by this paper
• An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP).

  2001cited by this paper
• Lymphatic transport of proteins after subcutaneous administration.

  2000cited by this paper
• Erythropoietin gene expression in different areas of the developing human central nervous system.

  2000cited by this paper
• Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients.

  1999cited by this paper
• Erythropoietin and Erythropoietin Receptor in the Developing Human Central Nervous System

  1998cited by this paper
• Lymphatic absorption of retinol in young, mature, and old rats: influence of dietary restriction

  1996cited by this paper
• Developmental differences in erythropoietin pharmacokinetics: increased clearance and distribution in fetal and neonatal sheep.

  1992cited by this paper
• Effect of Molecular Weight on the Lymphatic Absorption of Water-Soluble Compounds Following Subcutaneous Administration

  1990cited by this paper

• Development of an electrochemiluminescence assay to measure serum darbepoetin concentration in extremely preterm infants.

  2025cites this paper
• A prospective randomized pilot trial comparing weekly vs. biweekly Darbepoetin administration to preterm infants

  2025cites this paper
• A practical guide to reducing/eliminating red blood cell transfusions in the neonatal intensive care unit.

  2024cites this paper
• Current Status of Pharmacokinetic Research in Children: A Systematic Review of Clinical Trial Records.

  2022cites this paper
• Whether Immunostimulants Are Effective in Susceptible Children Suffering From Recurrent Respiratory Tract Infections: A Modeling Analysis Based on Literature Aggregate Data

  2021cites this paper
• Analysis of Time-Course, Dose-Effect, and Influencing Factors of Antidepressants in the Treatment of Acute Adult Patients With Major Depression

  2019cites this paper
• Medicinal Uses of Hematopoietic Growth Factors in Neonatal Medicine.

  2019cites this paper
• Embracing oligodendrocyte diversity in the context of perinatal injury

  2017cites this paper